HIF1A and Atherosclerotic lesion: DMOG is a competitive antagonist of α‐ketoglutarate that stabilizes HIF‐1α by inhibiting PHDs to prevent its hydroxylation.[47] LW6 is an (aryloxyacetylamino) benzoic acid derivative that inhibits HIF‐1α accumulation and expression.[48, 49] Herein, we observed that stabilizing HIF‐1α with DMOG aggravated atherosclerotic lesions in mice and reversed the protective effect of PC ablation on plaque progression.